title: [Genetic type of Helicobacter pylori and the efficacy of eradication therapy].
abstract: Helicobacter pylori is one of the most popular bacteria in the world. The H. pylori infection is an etiological factor of permanent changes in inflammatory of stomach mucous membrane, peptic ulcer of the stomach and duodenum disease and stomach cancer or mucosa associated lymphoid tissue from lymphoid tissue of mucous membrane. The strain bacteria which produce the protein CagA and cytotoxin VacA belong to the more pathogenic strains. The most successful method of treatment for H. pylori infection is an eradication of the bacteria.
  
  
  OBJECTIVE
  Was an evaluation of the influence which H. pylori genetic type (type I: CagA-positive, CagA-negative, VacA-positive, VacA-negative) has on efficacy of eradication therapy.
  
  
  METHODS
  214 of patients over the third year of life with symptoms of dyspepsia, of the upper part of the gastrointestinal tract was performed and H. pylori infection was proved in histopathological or (and) urease test and urea breath test. H. pylori identification was performed using PCR method for biopsy specimens of the gastric mucosa, estimating genetic type of the bacteria (CagA-positive, CagA-negative, VacA-positive, VacA-negative). Triple-drug eradication therapy was introduced. The efficiency of this treatment was checked after 6 weeks with the breath test.
  
  
  RESULTS
  The H. pylori infection was found in 101 patients (47.2%), 33 patients were infected with the strain type I (32.7%) and 68 patients (67.3%) with the strain type II. After the treatment the eradication of the infection was found at 71 patients (70.3%), lack of efficacy in H. pylori infection treatment was found at 30 patients (29.7%). Considerably higher percentage of eradicative infection was shown in the group of patients infected with the type II of H. pylori (76.5% vs. 58.8%, p < 0.04).
  
  
  CONCLUSIONS
  The effectiveness of eradication can be influenced by the genetic type of H. pylori. The better effects of eradicative treatment can be expected if one is infected with the strains of smaller virulence.
authors.affiliation: Nicolaus Copernicus University, Toruń, Poland. klped@cm.umk.pl
authors.forename: Monika
authors.initials: M
authors.lastname: Parzecka
authors.forename: Anna
authors.initials: A
authors.lastname: Szaflarska-Popławska
authors.forename: Grazyna
authors.initials: G
authors.lastname: Mierzwa
authors.forename: Marta
authors.initials: M
authors.lastname: Gorzkiewicz
authors.forename: Sylwia
authors.initials: S
authors.lastname: Łuczak
authors.forename: Tomasz
authors.initials: T
authors.lastname: Grzybowski
mesh_terms: D000293:Adolescent; D000942:Antigens, Bacterial / Q000096:biosynthesis; D001426:Bacterial Proteins / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics* / Q000378:metabolism / Q000472:pathogenicity; D006801:Humans; D013045:Species Specificity
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C074689:VacA protein, Helicobacter pylori; C080866:cagA protein, Helicobacter pylori